Syndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRC

Syndax Pharmaceuticals (SNDX) is demonstrating strong financial performance, with Q2 2025 sales up 43% quarter-over-quarter, primarily driven by the FDA approval of revumenib for r/r KMT2Ar AML patients. The company has a significant near-term catalyst with an FDA Priority Review decision expected by October 25, 2025, for its sNDA in r/r mNPM1 AML. Furthermore, Syndax is expanding its pipeline into metastatic MSS colorectal cancer, a major market opportunity with data anticipated by the end of 2025, reinforcing a bullish outlook based on strong execution and the potential for broader indications of revumenib.

Analysis

Syndax Pharmaceuticals (SNDX) is demonstrating significant commercial momentum, evidenced by a 43% quarter-over-quarter increase in Q2 2025 sales. This growth is directly attributable to the successful launch of revumenib following its FDA approval for treating r/r KMT2Ar AML. The company's outlook is bolstered by two major forthcoming catalysts. The most immediate is a near-term binary event: the FDA's Priority Review decision for a supplemental New Drug Application (sNDA) to expand revumenib's use to r/r mNPM1 AML, which has a PDUFA date of October 25, 2025. A positive decision would materially expand the drug's addressable market. Concurrently, Syndax is pursuing a longer-term growth vector by expanding into the large market of metastatic MSS colorectal cancer, with pivotal data expected by the end of 2025. This combination of strong initial sales, a clear regulatory catalyst, and a significant pipeline opportunity underpins the current bullish sentiment.

Key Decisions for Investors

• Investors should closely monitor the PDUFA decision on October 25, 2025, as a positive FDA outcome for revumenib's label expansion is a primary near-term catalyst that could significantly re-rate the stock.
• The reported 43% quarterly sales growth provides a strong fundamental basis for the current valuation, suggesting that existing long positions are well-supported by commercial execution ahead of the regulatory decision.
• Consider the end-of-2025 data release for the metastatic MSS colorectal cancer indication as the next major de-risking event for the company's long-term growth narrative.